<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305252</url>
  </required_header>
  <id_info>
    <org_study_id>SU-07152010-6565</org_study_id>
    <secondary_id>IRB protocol # 18305</secondary_id>
    <nct_id>NCT01305252</nct_id>
  </id_info>
  <brief_title>A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).</brief_title>
  <official_title>CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study Hypothesis:

      Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a
      traditional &quot;step-up&quot; approach.

      The study will evaluate:

        1. Impact of dual, upfront, therapy on cardiovascular parameters in PAH as gauged by
           cardiac magnetic resonance imaging (cMRI) at 24 weeks and event free survival at outcome
           at 48 weeks.

        2. Value of novel biomarkers (NT-pro BNP, Mts1/S100A4, and insulin resistance) and
           cutting-edge imaging technologies (cardiac MRI) as newer endpoints for clinical trials
           in PAH.

        3. Utility of longer clinical trial design with the use of combined clinical events as time
           to clinical worsening surrogate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48 week interventional study evaluating the effect of Dual therapy ( Treprostinil
      inhalations and Tadalafil) versus Mono therapy (Tadalafil). The impact of the therapy on
      cardiovascular parameters in PAH measured at 24 weeks and event free survival outcome at 48
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Right Ventricular Ejection Fraction</measure>
    <time_frame>Basline and 24 weeks</time_frame>
    <description>Effect of dual-upfront therapies versus mono-therapy on percent change of right ventricular function assesed by cardiac MRI (cMRI) at 24 weeks compared with the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Distance</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change in 6MWD during 24 week period compared between Tada and Tada+iTre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA/WHO Class</measure>
    <time_frame>Baseline and 48 week</time_frame>
    <description>At 48 week,WHO/NYHA functional class was assessed for change in WHO/NYHA functional class.Change NYHA is measured as decrease or increase in NYHA class in the subjects compared with baseline.
NYHA /WHO functional class is described below:
NYHA functional class I:no symptoms and no limitation in ordinary physical activity NYHA functional class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA functional class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity NYHA functional class IV:Severe limitations. Experiences symptoms even while at rest A higher functional class represent worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type Natriuretic Peptide (BNP)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>B-type Natriuretic peptide measures the percent change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>tadalafil alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil and treprostinil inhalations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treprostinil inhalations</intervention_name>
    <description>Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.</description>
    <arm_group_label>tadalafil and treprostinil inhalations</arm_group_label>
    <other_name>Tyvaso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
    <arm_group_label>tadalafil alone</arm_group_label>
    <arm_group_label>tadalafil and treprostinil inhalations</arm_group_label>
    <other_name>Adcirca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age 18 and &lt; 75 years at baseline visit.

          2. Diagnosis of Idiopathic PAH, Heritable PAH (including Hereditary Hemorrhagic
             Telangiectasia), Associated PAH (including collagen vascular disorders, drug+toxin
             exposure, repaired congenital heart disease repaired &gt; 5 years, portopulmonary
             disease, and human immunodeficiency virus (HIV) infection not on protease inhibitor).

          3. PAH treatment naïve including any prostacycline, endothelin receptor antagonist, or
             phosphodiesterase inhibitors within 12 months prior to enrollment.

          4. Previous Right Heart Catheterization that documented:

               1. Mean PAP; 25 mmHg.

               2. Pulmonary capillary wedge pressure &lt; 15 mmHg.

               3. Pulmonary Vascular Resistance; 3.0 Wood units or 240 dynes/sec/cm5 5.6MW
                  distances; 150 m and &lt; 450 meters.

        6. WHO functional class II or III as judged by principal investigators.

        Exclusion Criteria:

        Exclusion criteria:

          1. Group II - V pulmonary hypertension.

          2. PAH with unrepaired congenital heart defect.

          3. Current or prior PAH treatments within the last 6-12 months including experimental PAH
             therapies (including but not limited to tyrosine kinase inhibitors, rho-kinase
             inhibitors, phosphodiesterase inhibitors, prostacycline, or cGMP modulators).

          4. TLC &lt; 60% predicted; if TLC b/w 60 and 70% predicted, high resolution computed
             tomography must be available to exclude significant interstitial lung disease.

          5. FEV1 / FVC &lt; 70% predicted and FEV1 &lt; 60% predicted

          6. Significant left-sided heart disease (based on pre-trial Echocardiogram):

               1. Significant aortic or mitral valve disease

               2. Diastolic dysfunction ; Grade II C.LV systolic function &lt; 45%

             d. Pericardial constriction e. Restrictive cardiomyopathy f. Significant coronary
             disease with demonstrable ischemia

          7. Chronic renal insufficiency defined as an estimated creatinine clearance &lt; 30 ml/min
             (by MDRD equation)

          8. Current atrial arrhythmias

          9. Uncontrolled systemic hypertension: SBP &gt; 160 mm or DBP &gt; 100mm

         10. Severe hypotension: SBP &lt; 80 mmHg.

         11. Pregnant or breast-feeding

         12. Psychiatric, addictive, or other disorder that compromises patient's ability to
             provide informed consent, follow study protocol, and adhere to treatment instructions

         13. Co-morbid conditions that would impair a patient's exercise performance and ability to
             assess WHO functional class, including but not limited to chronic low-back pain or
             peripheral musculoskeletal problems.

         14. Contraindications for magnetic resonance imaging, including significant
             claustrophobia, implanted metallic objects, or others as per Appendix X).

         15. Known allergy to treprostinil or tadalafil.

         16. Active oral nitrate use.

         17. Diabetes mellitus.

         18. Planned initiation of cardiac or pulmonary rehabilitation during period of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roham T. Zamanian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Roham T. Zamanian</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil Alone</title>
          <description>tadalafil 40mg QD
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
        <group group_id="P2">
          <title>Tadalafil and Treprostinil Inhalations</title>
          <description>inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil Alone</title>
          <description>tadalafil 40mg QD
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
        <group group_id="B2">
          <title>Tadalafil and Treprostinil Inhalations</title>
          <description>inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="11.4"/>
                    <measurement group_id="B2" value="52.1" spread="9.7"/>
                    <measurement group_id="B3" value="51.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Right Ventricular Ejection Fraction</title>
        <description>Effect of dual-upfront therapies versus mono-therapy on percent change of right ventricular function assesed by cardiac MRI (cMRI) at 24 weeks compared with the baseline.</description>
        <time_frame>Basline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil and Treprostinil Inhalations</title>
            <description>Inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Alone</title>
            <description>Tadalafil 40mg QD
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular Ejection Fraction</title>
          <description>Effect of dual-upfront therapies versus mono-therapy on percent change of right ventricular function assesed by cardiac MRI (cMRI) at 24 weeks compared with the baseline.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" lower_limit="0.95" upper_limit="13.96"/>
                    <measurement group_id="O2" value="2.8" lower_limit="-1.49" upper_limit="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walk Distance</title>
        <description>Change in 6MWD during 24 week period compared between Tada and Tada+iTre.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Alone</title>
            <description>Tadalafil 40mg QD
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil and Treprostinil Inhalations</title>
            <description>Inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Distance</title>
          <description>Change in 6MWD during 24 week period compared between Tada and Tada+iTre.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.63" lower_limit="23.40" upper_limit="141.86"/>
                    <measurement group_id="O2" value="87.69" lower_limit="6.98" upper_limit="168.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</title>
        <description>Change from baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil and Treprostinil Inhalations</title>
            <description>Inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Alone</title>
            <description>Tadalafil 40mg QD
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</title>
          <description>Change from baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1239" spread="1393"/>
                    <measurement group_id="O2" value="988.4" spread="827.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NYHA/WHO Class</title>
        <description>At 48 week,WHO/NYHA functional class was assessed for change in WHO/NYHA functional class.Change NYHA is measured as decrease or increase in NYHA class in the subjects compared with baseline.
NYHA /WHO functional class is described below:
NYHA functional class I:no symptoms and no limitation in ordinary physical activity NYHA functional class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA functional class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity NYHA functional class IV:Severe limitations. Experiences symptoms even while at rest A higher functional class represent worse symptoms.</description>
        <time_frame>Baseline and 48 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Alone</title>
            <description>Tadalafil 40mg QD
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil and Treprostinil Inhalations</title>
            <description>Inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NYHA/WHO Class</title>
          <description>At 48 week,WHO/NYHA functional class was assessed for change in WHO/NYHA functional class.Change NYHA is measured as decrease or increase in NYHA class in the subjects compared with baseline.
NYHA /WHO functional class is described below:
NYHA functional class I:no symptoms and no limitation in ordinary physical activity NYHA functional class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA functional class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity NYHA functional class IV:Severe limitations. Experiences symptoms even while at rest A higher functional class represent worse symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B-type Natriuretic Peptide (BNP)</title>
        <description>B-type Natriuretic peptide measures the percent change from baseline.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil Alone</title>
            <description>tadalafil 40mg QD
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil and Treprostinil Inhalations</title>
            <description>inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>B-type Natriuretic Peptide (BNP)</title>
          <description>B-type Natriuretic peptide measures the percent change from baseline.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374" spread="133.8"/>
                    <measurement group_id="O2" value="295.6" spread="133.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>initial 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil Alone</title>
          <description>tadalafil 40mg QD
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
        <group group_id="E2">
          <title>Tadalafil and Treprostinil Inhalations</title>
          <description>inhaled treprostinil: Treprostinil inhalation QID starting at 3 breaths per inhalation &amp; gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
tadalafil: tadalafil 20mg QD PO increasing to 40mg QD as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death attributed to septic shock and ensuring renal failure.Not clinically deemed to be related to study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion/allergic Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dental infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations: small,2 center study,Placebo Un-blinded,Limited event rates/Time to clinical worsening and harmonization of measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Roham Zamanian, MD, FCCP</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650- 725-5495</phone>
      <email>zamanian@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

